Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma

Fig. 6

Co-treatment of olaparib and doxorubicin inhibited growth of KHOS/NP osteosarcoma cells in mice. a The gross and histologic findings of KHOS/NP osteosarcoma around the knee of mice. The tumor volume (b) and tumor weight (c) were significantly decreased with treatment of 10 μM olaparib or 0.2 μM doxorubicin. Especially, tumor growth was significantly decreased with co-treatment of 10 μM olaparib and 0.2 μM doxorubicin in mice. *, P < 0.05; **, P < 0.001

Back to article page